Genital Herpes Pipeline Landscape: Insights into Emerging Therapies, Growth Variables, Commercial Assessment and Key Pharmaceutical Companies Active in the Space

Los Angeles, USA, July 05, 2021 (GLOBE NEWSWIRE) -- Genital Herpes Pipeline Landscape: Insights into Emerging Therapies, Growth Variables, Commercial Assessment and Key Pharmaceutical Companies Active in the Space

The Genital Herpes pipeline landscape offers a rich product portfolio with novel therapy MoAs such as Immunomodulators, Virus internalization inhibitors, DNA helicase-primase inhibitors, Immunostimulants, and others in the trials. 

DelveInsight's ‘Genital Herpes Pipeline Insights' report presents an exhaustive coverage of the available therapies, Genital Herpes emerging therapies in different phases of clinical development, key companies working in the Genital Herpes pipeline domain, and future potential of the space. 

Some of the notable pointers extracted from the Genital Herpes Pipeline report:

• DelveInsight's analysis depicts a robust Genital Herpes Pipeline with 25+ active players in the domain working on 25+ pipeline therapies. 
• Key Genital Herpes pipeline therapies such as HSV 2 Vaccines, RVx-201, NE HSV-2 Vaccine, HDIT 101, Pritelivir, UB-621, and others are under investigation in different phases of clinical trials for the treatment of Genital Herpes. 
• Sanofi, Rational Vaccines, BlueWillow Biologics, Heidelberg, ImmunoTherapeutics, AiCuris, United Biopharma, among several others, are some of the key prominent pharma players working in the domain. 
• In May 2021, X-Vax Technology announced that it is preparing to submit an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for its experimental vaccine against herpes simplex virus 1 and 2 (HSV-1 and -2).  
• In June 2020, AiCuris was granted Breakthrough Therapy Designation by U.S. FDA for Pritelivir for the treatment of HSV infections in immunocompromised patients.  

Request for Sample to know more about the therapies expected to grab the maximum patient pool @ Genital Herpes Emerging Therapies and Forecast 

The Genital Herpes Pipeline reports offer a holistic scenario of the ongoing clinical trials, partnerships taking place in the domain, recent happenings in space, and growth prospects across the Genital Herpes domain.

Genital Herpes: Overview

Genital Herpes or Herpes genitalis is one of the most common sexually transmitted infections. It is caused by the herpes simplex virus type 2 (HSV-2) and herpes simplex virus type 1 (HSV-1). 

The primary mode of transmission of both HSV-1 and HSV-2 is through direct contact. Initial infection with HSV-1 occurs most often during childhood following the disappearance of maternal antibodies during the first year of life.

Discover more about the disease, treatments, and pipeline therapies @ Genital Herpes Pipeline Assessment 

Genital Herpes Pipeline Drugs 

Request for Sample to know more @ Genital Herpes Pipeline Analysis, Key Companies, and Futuristic Trends 

Genital Herpes Therapeutics Assessment 

The Genital Herpes Pipeline report presents a kaleidoscopic view of the Genital Herpes emerging novel therapies segmented by Stage, Product Type, Route of Administration, Molecule Type, Target, and Mechanism of Action.

By Product Type

• Mono
• Mono/Combination

By Stage

• Discovery 
• Pre-clinical
• IND
• Phase I
• Phase II
• Phase III
• Pre-registration

By Molecule Type 

• Peptides 
• Small molecules
• Vaccine
• Monoclonal antibodies

By Route of Administration

• Oral
• Subcutaneous
• Intravenous
• Intranasal 
• Intramuscular

By Mechanism of Action

• Immunomodulators
• Immunomodulators; Virus internalization inhibitors
• DNA helicase-primase inhibitors
• Immunostimulants

By Targets

• DNA helicase-primase
• Virus internalization

For rich insights into merging therapies and assessment, visit Genital Herpes Pipeline: Emerging Novel Therapies 

Scope of the Genital Herpes Pipeline Report

Coverage: Global
Key Players: Sanofi, Rational Vaccines, BlueWillow Biologics, Heidelberg ImmunoTherapeutics, AiCuris, United Biopharma, among others.
Key Genital Herpes Pipeline Therapies: HSV 2 Vaccines, RVx-201, NE HSV-2 Vaccine, HDIT 101, Pritelivir, UB-621, and others.

Discover more about the scope of the report @ Genital Herpes Emerging Therapies, Treatments, and Ongoing Clinical Trials 

Table of Contents 

Learn more about the report offerings @ Genital Herpes Pipeline Therapies and Emerging Trends 

Audit the market before venturing with DelveInsight's Due Diligence Services  

Related Reports

Genital Herpes Market
DelveInsight's "Genital Herpes (Genital Herpes) Market Insights, Epidemiology and Market Forecast-2028" report.

Herpes Genitalis Market
DelveInsight's "Herpes Genitalis - Market Insights, Epidemiology, and Market Forecast-2030" report.

Herpes Labialis Market
DelveInsight's "Herpes Labialis - Market Insights, Epidemiology, and Market Forecast-2030" report.

Herpes Simplex Market
DelveInsight's "Herpes Simplex - Market Insights, Epidemiology, and Market Forecast-2030" report.

Herpes Zoster Oticus Market
DelveInsight's "Herpes Zoster Oticus - Market Insights, Epidemiology, and Market Forecast-2030" report.

Herpes Zoster Market
DelveInsight's "Herpes Zoster - Market Insights, Epidemiology, and Market Forecast-2030" report. 

Recurrent Herpes Labialis Market
DelveInsight's "Recurrent Herpes Labialis - Market Insights, Epidemiology, and Market Forecast-2030" report.

Browse through our posts 

Rising Burden of Sexually Transmitted Diseases (STDs)
Key pharma companies such as Evofem Biosciences, QureTechBio, Vault Pharma, Squarex Pharma, AiCuris, United BioPharma, Merck, United Biopharma, ViiV Healthcare, Johnson & Johnson, among others are diligently working to lower the burden on the healthcare industry due to STDs. Know which company is set to emerge as the leader in the space. 

Insights into Non-Small Cell Lung Cancer Market  
What therapies are in the market that is expected to gain maximum traction in the Non-Small Cell Lung Cancer Market? 

Angelman Syndrome Medications
Discover more about the novel approaches in the  Angelman Syndrome Medications Market.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.  Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

For more insights, visit Pharma, Healthcare, and Biotech News 

Contact Us

Shruti Thakur 

info@delveinsight.com 

+1(919)321-6187 

www.delveinsight.com